Market Cap: $27.48B
GA
Genmab A/S
GMAB
NASDAQ (NASDAQ Global Select)USD
Market Cap: $27.48B
Genmab pins Q4 disclosure to Feb. 17 as forum for pipeline and partnership updates Main development: Q4 earnings call becomes focal point for clinical and commercial progress Genmab schedules its four…
Genmab Partners with Anthropic to Accelerate Drug Discovery Through AI Innovation Genmab, a leading biotechnology company, enters a strategic partnership with the artificial intelligence firm Anthropi…
Incyte's Groundbreaking Trial Results Signal a New Era in DLBCL Treatment Incyte Corporation announces compelling topline results from its pivotal Phase 3 frontMIND trial, showcasing the effectiveness…
Incyte's Promising Advances in DLBCL Treatment Incyte Corporation recently announces the topline results from its pivotal Phase 3 frontMIND trial, focusing on the efficacy of tafasitamab (Monjuvi/Minj…
Genmab Halts Development of Acasunlimab in Strategic Shift Genmab A/S announces a significant decision to discontinue the clinical development of acasunlimab, a monoclonal antibody aimed at treating v…
Advancements in CAR T Cell Therapy: A New Hope for Marginal Zone Lymphoma Patients The recent approval by the U.S. Food and Drug Administration (FDA) of Bristol Myers Squibb's CAR T cell therapy, Brey…
FDA Approval of Breyanzi Marks a Milestone in Marginal Zone Lymphoma Treatment On Thursday, the U.S. Food and Drug Administration (FDA) granted approval to Bristol Myers Squibb & Co. for its CAR T cel…
Breakthrough CAR T Cell Therapy Approved for Marginal Zone Lymphoma Patients In a significant advancement for the field of oncology, the U.S. Food and Drug Administration (FDA) grants approval to Bris…
Genmab's Epkinly Approval Marks a New Era in Follicular Lymphoma Treatment In a pivotal development for cancer care, the U.S. Food and Drug Administration (FDA) grants approval to Genmab A/S for its i…
Genmab Expands Treatment Options for Follicular Lymphoma with FDA Approval of Epkinly Genmab A/S has made a noteworthy stride in oncology with the recent approval from the U.S. Food and Drug Administr…
Genmab Advances Cancer Treatment with Promising Rinatabart Sesutecan Data Genmab A/S (NASDAQ: GMAB) recently announces updated findings from cohort B2 of its Phase 1/2 RAINFOL-01 trial, which investig…
Genmab Advances Oncology Research with Promising Rinatabart Sesutecan Data Genmab A/S has recently updated the medical community on the promising results from cohort B2 of the Phase 1/2 RAINFOL-01 tri…
Genmab Advances Oncology Research with Promising Trial Results Genmab A/S (NASDAQ: GMAB) recently announces updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial, which investigates the effica…
Genmab's Strategic Acquisition of Merus: A Game Changer in Oncology Genmab, a leading biotech firm, takes a significant step in the oncology landscape with its announcement of a definitive agreement t…
Genmab's Strategic Acquisition: A Bold Step into Oncology Genmab A/S (NASDAQ: GMAB) recently announces its decision to acquire Merus N.V. (NASDAQ: MRUS) in a transformative all-cash transaction valued…
Genmab Strengthens Oncology Pipeline with Merus Acquisition In a significant strategic move, Genmab A/S has announced its acquisition of Merus N.V. for approximately $8 billion in cash, marking one of…
Genmab's Divergent Analyst Opinions Highlight Industry Uncertainties In the past three months, Genmab, a prominent player in the biotechnology sector, experiences a spectrum of evaluations from indust…
Genmab's Diverse Analyst Opinions Reflect Industry Complexities In recent months, Genmab (GMAB) has garnered attention from analysts, who present a mixed bag of evaluations regarding the biotechnology…
Genmab's Diverse Analyst Opinions Reflect Industry Complexity Genmab, a prominent player in the biotechnology sector, finds itself under the scrutiny of analysts who present a spectrum of perspectives…
Genmab Recognized for Innovative Practices in Bio-IT Sector Genmab, a prominent player in the biotechnology industry, receives accolades at the upcoming Bio-IT World Conference & Expo in Boston, sched…
Breakthroughs in B-Cell Malignancy Treatment Highlighted at ASH Meeting Genmab A/S is set to make a significant impact at the upcoming 66th Annual Meeting and Exposition of the American Society of Hem…